pentaray mapping catheter (Biosense Webster)
86
Structured Review
Biosense Webster
pentaray mapping catheter
Pentaray Mapping Catheter, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mapping+catheter+pentaray/catheter+mapping+multipolar+%E2%80%A2/pmc13270936-44-6-23
Average 86 stars, based on 1 article reviews
Pentaray Mapping Catheter, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mapping+catheter+pentaray/catheter+mapping+multipolar+%E2%80%A2/pmc13270936-44-6-23
Average 86 stars, based on 1 article reviews
pentaray mapping catheter - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Activation Assay:Article Title: Left Atrial Low-Voltage Extent Predicts the Recurrence of Supraventricular Arrhythmias Article Snippet: When considering both mapping catheters separately, the best predictive value for Article Title: Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED registry). Article Snippet: A Article Title: Evaluating the Prognostic Significance of Cystatin C Level Variations Pre‐ and Post‐Radiofrequency Catheter Ablation in the Recurrence of Persistent Atrial Fibrillation Article Snippet: The Article Title: Novel systematic processing of cardiac magnetic resonance imaging identifies target regions associated with infarct-related ventricular tachycardia Article Snippet: Mapping data were obtained with the ablation catheter (Navistar Thermocool, Biosense Webster; Tacticath or FlexAbility, Abbott) or a Article Title: Prognostic value of electroanatomic-guided endomyocardial biopsy in patients with myocarditis, arrhythmogenic cardiomyopathy and non dilated left ventricular cardiomyopathy. Article Snippet: A wide variety of non-invasive and invasive techniques for SCD risk stratification in non ischemic cardiomyopathy (NICM) have been proposed, including left ventricular (LV) ejection fraction, QRS duration, late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) and invasive electrophysiologic study with or without three-dimensional electroanatomic mapping (3D-EAM), to identify and characterize the arrhythmogenic substrate.. There is still no clear consensus on the risk stratification in this clinical setting.. The aim of our study is to characterize the 3D-EAM substrate in patients with the same clinical presentation of unexplained complex VAs and NICM using CMR, three-dimensional electranatomic mapping (3D-EAM) in association with endomyocardial biopsy (EMB) and genetic screening, as a more precise and early diagnostic assessment may provide important subsequent prognostic impact. |